Cure My Disease

Don't miss your cure!

 Log in / Sign up

New IV drug tested for severe eczema relief

NCT ID NCT03822832

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

Summary

This study tested an investigational drug called BI 655130, given by IV infusion, to see if it is safe and effective for adults with moderate to severe atopic dermatitis (eczema). It compared the drug to a placebo in 51 patients over 16 weeks. The main goal was to see how much the treatment could reduce the severity and area of the skin rash.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aichi Medical University Hospital

    Aichi, Nagakute, 480-1195, Japan

  • Center for Clinical Studies

    Webster, Texas, 77598, United States

  • Center for Dermatology and Plastic Surgery

    Scottsdale, Arizona, 85260, United States

  • Clinical Physiology Associates

    Fort Myers, Florida, 33912, United States

  • Dermatology Treatment and Research Center, PA

    Dallas, Texas, 75230, United States

  • Finlay Medical Research Corp

    Miami, Florida, 33126, United States

  • ForCare Clinical Research, Inc.

    Tampa, Florida, 33613, United States

  • Hosui General Medical Clinic

    Hokkaido, Sapporo, 064-0807, Japan

  • Innovaderm Research Inc.

    Montreal, Quebec, H2X 2V1, Canada

  • Kurume University Hospital

    Fukuoka, Kurume, 830-0011, Japan

  • Nagasaki University Hospital

    Nagasaki, Nagasaki, 852-8501, Japan

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, Fukuoka, 810-8563, Japan

  • NewLab Clinical Research Inc.

    St. John's, Newfoundland and Labrador, A1C 2H5, Canada

  • Osaka City University Hospital

    Osaka, Osaka, 545- 8586, Japan

  • Progressive Clinical Research

    San Antonio, Texas, 78213, United States

  • Showa University Hospital

    Tokyo, Shinagawa-ku, 142-8666, Japan

  • Tennocho Ekimae Dermatology and Allergology

    Kanagawa, Yokohama, 240-0004, Japan

  • The Indiana Clinical Trials Center, PC

    Plainfield, Indiana, 46168, United States

  • Tokyo Medical University Hachioji Medical Center

    Tokyo, Hachioji, 193-0998, Japan

  • Unity Clinical Research

    Oklahoma City, Oklahoma, 73118, United States

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, Kyoto, 602-8566, Japan

  • University of Alberta Hospital (University of Alberta)

    Edmonton, Alberta, T6G 2B7, Canada

  • University of South Florida

    Tampa, Florida, 33612, United States

Conditions

Explore the condition pages connected to this study.

DERMATITIS, ATOPIC